Investors hunting for yield during uncertain times need to look beyond high dividends to individual company fundamentals. (Stocks include: T, MO, VZ )
Adam Feuerstein, senior columnist for TheStreet, explains why Medivation is the next big thing in biotech. (Featuring MDVN)
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Treehouse Leaves Doubts; RIM's Seismic Silliness; Martha vs. Macy's; McDonald's Twitter Tragedy; Volt Loses Charge.
As European debt woes continue to linger and the U.S. economy struggles to gain solid footing, 2012 promises to be another volatile year. Here are the major events that have impact global markets so far this year.
TheStreet screened 10 banks that ranked the highest on 'returns on average assets' in 2011. (Stocks include WFC, CBSH)
JPMorgan says shares of Chesapeake Energy will decline to under $15, territory it hasn't seen since 2004.
The shares are riding high in 2012.
A recent report analyzes prospects for CSX, Qualcomm and five others.
Sean Halper of Halper Capital Management gives his top three retail names, plus a surprising short.